

**Approval of OAC Triple Therapy
as *Helicobacter pylori* Eradication Treatment**

As an eradication treatment of *Helicobacter pylori* recognized as effective for the inhibition of recurrence of peptic ulcer, a triple therapy using 3 medicines such as omeprazole, amoxicillin and clarithromycin, (OAC triple therapy), received approval on April 11, for gastric ulcer and duodenum ulcer infected with *Helicobacter pylori*. The OAC triple therapy is a regimen on which high eradication rate and tolerability was observed in MACH 1 study (a large-scale clinical study) conducted mainly in Europe.

The OAC triple therapy in Japanese patient was evaluated in domestic and overseas clinical studies. Effective eradication rate and tolerability was observed when 20 mg of omeprazole, 750 mg of amoxicillin and 400 mg of clarithromycin were orally administered together twice a day for 7 days,

Since the OAC triple therapy which has become the global standard is now subject to insurance coverage in Japan, we expect that it is a good news to the patients with repeated recurrence of gastric and duodenum ulcer who are *Helicobacter pylori* positive.

The medicines approved to use in the OAC triple therapy are as follows:

Generics Name	Product Name	Manufacturing/Marketing Company
Omeprazole	Omepral Tab 10 Omepral Tab 20	AstraZeneca K.K.
	Omeprazon Tab 10mg Omeprazon Tab 20mg	Mitsubishi Pharma Corporation
	Pasetocin Tablets 250 Pasetocin Capsules	Kyowa Hakko Kogyo Co., Ltd.
Amoxicillin	Sawacillin Tablets 250mg Sawacillin Capsules	Showa Kako Corporation - Manufacturing Fujisawa Pharmaceutical Co., Ltd. - Marketing
	Amoxicillin Cap, 「TOWA」	Towa Pharmaceutical Co., Ltd.
	Clarithromycin	Clarith Tab. 200
Klaricid Tab. 200mg		Dainabot Co., Ltd – Manufacturing Dainippon Pharmaceutical Co., Ltd. - Marketing

This press release is jointly made by following 9 companies. For further enquiries, please contact:

*PR&Communications, AstraZeneca K.K.
Office of Public Relations & Investor Relations, Corporate Affairs
Division, Mitsubishi Pharma Corporation
Corporate Communications Dept., Kyowa Hakko Kogyo Co., Ltd.
Towa Pharmaceutical Co., Ltd
Public Relations Section, Taisho Pharmaceutical Co., Ltd.
Marketing Dept., Dainabot Co., Ltd.*

*Phone: 06-6453-8011
Phone: 06-6201-1696
Phone: 03-3282-1903
Phone: 06-6900-9116
Phone: 03-3985-1115
Phone: 06-6942-2065*